256 related articles for article (PubMed ID: 12819382)
1. Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors.
Lee CH; Kweon OK
J Vet Sci; 2002 Dec; 3(4):321-5. PubMed ID: 12819382
[TBL] [Abstract][Full Text] [Related]
2. Prognostic status of p53 gene mutation in canine mammary carcinoma.
Wakui S; Muto T; Yokoo K; Yokoo R; Takahashi H; Masaoka T; Hano H; Furusato M
Anticancer Res; 2001; 21(1B):611-6. PubMed ID: 11299814
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic alterations in eight mammary tumors and tumor-suppressor gene p53 mutation in one mammary tumor from dogs.
Mayr B; Dressler A; Reifinger M; Feil C
Am J Vet Res; 1998 Jan; 59(1):69-78. PubMed ID: 9442248
[TBL] [Abstract][Full Text] [Related]
4. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors.
Lee CH; Kim WH; Lim JH; Kang MS; Kim DY; Kweon OK
J Vet Sci; 2004 Mar; 5(1):63-9. PubMed ID: 15028887
[TBL] [Abstract][Full Text] [Related]
5. Identification of tumour-associated and germ line p53 mutations in canine mammary cancer.
Veldhoen N; Watterson J; Brash M; Milner J
Br J Cancer; 1999 Oct; 81(3):409-15. PubMed ID: 10507764
[TBL] [Abstract][Full Text] [Related]
6. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog.
Van Leeuwen IS; Hellmèn E; Cornelisse CJ; Van den Burgh B; Rutteman GR
Anticancer Res; 1996; 16(6B):3737-44. PubMed ID: 9042250
[TBL] [Abstract][Full Text] [Related]
7. p53 gene mutations occurring in spontaneous benign and malignant mammary tumors of the dog.
Muto T; Wakui S; Takahashi H; Maekawa S; Masaoka T; Ushigome S; Furusato M
Vet Pathol; 2000 May; 37(3):248-53. PubMed ID: 10810989
[TBL] [Abstract][Full Text] [Related]
8. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
9. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
10. Novel canine tumour suppressor gene p53 mutations in cases of skin and mammary neoplasms.
Mayr B; Reifinger M; Alton K
Vet Res Commun; 1999 Aug; 23(5):285-91. PubMed ID: 10493115
[TBL] [Abstract][Full Text] [Related]
11. Presence of p53 mutations in feline neoplasms.
Mayr B; Blauensteiner J; Edlinger A; Reifinger M; Alton K; Schaffner G; Brem G
Res Vet Sci; 2000 Feb; 68(1):63-70. PubMed ID: 10684760
[TBL] [Abstract][Full Text] [Related]
12. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
[TBL] [Abstract][Full Text] [Related]
13. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.
Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349
[TBL] [Abstract][Full Text] [Related]
14. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
15. Single nucleotide variation in exon 11 of canine BRCA2 in healthy and cancerous mammary tissue.
Hsu WL; Huang YH; Chang TJ; Wong ML; Chang SC
Vet J; 2010 Jun; 184(3):351-6. PubMed ID: 19944633
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations selected in vivo when mouse mammary epithelial cells form hyperplastic outgrowths are not necessary for establishment of mammary cell lines in vitro.
Ozbun MA; Jerry DJ; Kittrell FS; Medina D; Butel JS
Cancer Res; 1993 Apr; 53(7):1646-52. PubMed ID: 8453637
[TBL] [Abstract][Full Text] [Related]
17. Infrequent mutation of the p53 gene in fibrous tumors of infancy and childhood.
Boman F; Peters J; Ragge N; Triche T
Diagn Mol Pathol; 1993 Mar; 2(1):14-22. PubMed ID: 8287221
[TBL] [Abstract][Full Text] [Related]
18. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou ES; Levesque MA; Katsaros D; Angelopoulou K; Yu H; Genta F; Arisio R; Massobrio M; Bharaj B; Diamandis EP
Anticancer Res; 1999; 19(1B):749-56. PubMed ID: 10216487
[TBL] [Abstract][Full Text] [Related]
19. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
20. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
